PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

BACKGROUND: Eribulin is a microtubule-targeting agent approved for the treatment of advanced or metastatic breast cancer (BC) previously treated with anthracycline- and taxane-based regimens. PIK3CA mutation is associated with worse response to chemotherapy in oestrogen receptor-positive (ER+)/human...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Gris-Oliver, Albert, Ibrahim, Yasir H., Rivas, Martín A., García-García, Celina, Sánchez-Guixé, Mònica, Ruiz-Pace, Fiorella, Viaplana, Cristina, Pérez-García, José M., Llombart-Cussac, Antonio, Grueso, Judit, Parés, Mireia, Guzmán, Marta, Rodríguez, Olga, Anton, Pilar, Cozar, Patricia, Calvo, Maria Teresa, Bruna, Alejandra, Arribas, Joaquín, Caldas, Carlos, Dienstmann, Rodrigo, Nuciforo, Paolo, Oliveira, Mafalda, Cortés, Javier, Serra, Violeta
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8076303/
https://ncbi.nlm.nih.gov/pubmed/33723394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01293-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados